X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Merck Steps Up Its Battle Against Maternal Mortality

Content Team by Content Team
11th January 2022
in News
Merck Steps Up Its Battle Against Maternal Mortality

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A startling figure indeed when we say that around the globe, a lady dies every 2 minutes, due to complications arising from childbirth and pregnancy. However, the fact remains that most of the situations are preventable, and to be exact Pharmaceutical major Merck has given it all in the last decade to be the change. They have spent a whopping $500 million through an initiative known as Merck for Mothers that began in 2011, which is pledging another $150 million to the cause which also includes $15 million that is solely supporting maternal health gamut, particularly in the US.

This move also comes after Merck detached itself from the women’s health unit called Organon the last summer. Due to the latest investment, Merck seems to aim to take stock of worsening health care inequalities, especially in maternal health during the pandemic, and thereby elevate the prenatal health services among 25 million women through 2025. And to be expansive, the latest rounds of funding shall again be filtered into countries with the greatest needs like the US, India, Nigeria, and Kenya.

In December, at the time of Maternal Health Day of Action, VP Kamala Harris challenged all the three, public, private as well as nonprofit sectors to join hands against the maternity mortality crisis, which according to her is a growing concern in the US even as the rates are dropping elsewhere. It is predicted that Merck’s thrust into Biden-Harris Maternal CTA will develop its $20 million initiative on Safer Childbirth Cities. The program has already passed over a $1 million grant for each of the 20 community-based partnerships which have already begun their push towards working for at-risk women.

As it happened in the initiative before, the funding will be focused on inequalities in health that exist in communities where maternal mortality rates are higher. It is well to be noted that in the US, Black women are two-three times more likely to die of pregnancy complications and childbirth as compared to white women. In New York, for example, black women are almost 12 times more likely to succumb to complications than white women.

Previous Post

Israel PM Says Second Booster Swells Antibodies Five Times

Next Post

Amidst The Surge, Deltacron Variant Crops-Up In Cyprus

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Amidst The Surge, Deltacron Variant Crops-Up In Cyprus

Amidst The Surge, Deltacron Variant Crops-Up In Cyprus

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In